牛玲玲;金艺凤;

• 1:皖南医学院附属弋矶山医院呼吸内科

摘要(Abstract)：

与其它恶性肿瘤相比,肺癌不仅有着第一的发病率,在死亡率上也是位居榜首,给人类的生命健康带来了极大的威胁。近年来随着医学研究的不断发展,在针对肺癌的治疗中逐渐出现了靶向治疗和免疫治疗两种新的方法。本文主要回顾和总结了肺癌的靶向治疗及免疫治疗进展相关研究成果。

关键词(KeyWords)： 肺癌;靶向治疗;免疫治疗

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 牛玲玲;金艺凤;

Email:

DOI: 10.13799/j.cnki.mdjyxyxb.2019.01.033

参考文献(References)：

• [1]钟磊,师健友.耐吉非替尼的HCC827GR细胞的高效诱导及其药理学特性[J].中国药理学通报.2016,(9):1284-1288.
• [2]ALTUNDAG O,ALTUNDAG K,BORUBAN C,et al.Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein:a Phase II clinical trial[J].Cancer,2005,104(9):2033-2034.
• [3]BRIDGES K A,CHEN X,LIU H,et al.MK-8776,a novel chk1 kinase inhibitor,radiosensitizes p53-defective human tumor cells[J].Oncotarget,2016,7(44):71660-71672.
• [4]GEORGE J,LIM J S,JANG S J,et al.Comprehensive genomic profiles of small cell lung cancer[J].Nature,2015,524(7563):47-53.
• [5]SEMENOVA E A,NAGEL R,BERNS A.Origins,genetic landscape,and emerging therapies of small cell lung cancer[J].Genes Dev,2015,29(14):1447-1462.
• [6]NAKAJIMA W,SHARMA K,HICKS M A,et al.Combination with vorinostat overcomes ABT-263(navitoclax)resistance of small cell lung cancer[J].Cancer Biol Ther,2016,17(1):27-35.
• [7]ROSELL R,CARCERENY E,GERVAIS R,et al.Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC):a multicentre,open-label,randomised phase 3 trial[J].Lancet Oncol,2012,13(3):239-246.
• [8]ZHOU C,WU Y L,CHEN G,et al.Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer(OPTIMAL,CTONG-0802):a multicentre,open-label,randomised,phase 3 study[J].Lancet Oncol,2011,12(8):735-742.
• [9]YANG J C,HIRSH V,SCHULER M,et al.Symptom control and quality of life in LUX-Lung 3:a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations[J].J Clin Oncol,2013,31(27):3342-3350.
• [10]JACKMAN D,PAO W,RIELY G J,et al.Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer[J].J Clin Oncol,2010,28(2):357-60.
• [11]CREQUIT P,RUPPERT A M,ROZENSZTAJN N,et al.EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients[J].Lung Cancer,2016,96:74-77.
• [12]KWAK E L,SORDELLA R,BELL D W,et al.Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib[J].Proc Natl Acad Sci U S A,2005,102(21):7665-7670.
• [13]MULLER I B,LANGEN A J,GIOVANNETTI E,et al.Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer:clinical impact of alectinib[J].Onco Targets Ther,2017,10:4535-4541.
• [14]SODA M,CHOI Y L,ENOMOTO M,et al.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer[J].Nature,2007,448(7153):561-566.
• [15]蒋涛,周彩存.ALK阳性非小细胞肺癌患者克唑替尼耐药的机制和治疗措施[J].中国肺癌杂志,2015,(2):69-74.
• [16]SANDLER A,GRAY R,PERRY M C,et al.Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer[J].NEngl J Med,2006,355(24):2542-2550.
• [17]Herbst R S,O'Neill V J,Fehrenbacher L,et al.Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer[J].J Clin Oncol,2007,25(30):4743-4750.
• [18]KILLOCK D.Lung Cancer:Frontline nivolumab-CheckMate 026ends in stalemate[J].Nat Rev Clin Oncol,2017,14(8):458-459.
• [19]BOTTOMLEY A,DEBRUYNE C,FELIP E,et al.Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer[J].Eur J Cancer,2008,44(15):2178-2184.
• [20]OVERACRE A E,CHIKINA M,DADEY R E,et al.Interferon-γDrives Treg Fragility to Promote Anti-tumor Immunity[J].Cell,2017,169(6):1130-1141.
• [21]KATO M,GOTO S,SOMA G.Lymphokine-activated killer cell therapy combined with high-dose glucocorticoid showed clinical efficacy towards advanced lung carcinoma[J].Anticancer Res,2010,30(8):3125-3128.
• [22]SAKAMOTO M,NAKAJIMA J,MURAKAWA T,et al.Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expandedγδTcells:a phase I clinical study[J].J Immunother,2011,34(2):202-211.
• [23]BEATTY G L,O'HARA M.Chimeric antigen receptor-modified Tcells for the treatment of solid tumors:Defining the challenges and next steps[J].Pharmacol Ther,2016,166:30-39.